Univentis Medicare Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Univentis Medicare Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $8.1M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Univentis Medicare Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $8.1M Trade | TransData Nexus

Univentis Medicare Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $8.1M Total Trade · DGFT Verified

Univentis Medicare Limited is an Indian pharmaceutical exporter with a total trade value of $8.1M across 2 products in 1 therapeutic categories. Based on 161 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ceftriaxone ($5.5M), Cefixime ($2.5M), .

Univentis Medicare Limited — Export Portfolio & Destination Treemap

Univentis Medicare Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Univentis Medicare Limited? — Company Overview & Market Position

Univentis Medicare Limited is an Indian pharmaceutical company established on July 3, 2015, in Panvel, Maharashtra. The company is registered under the Corporate Identification Number (CIN) U24232MH2015PLC402722. It operates as a public unlisted company with an authorized capital of ₹5 million and a paid-up capital of ₹1.5 million. The registered office is located at Plot No. L6, MIDC Road, Taloja, Panvel, Maharashtra 410208, India.

Univentis Medicare Limited specializes in the marketing and sale of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's product portfolio is concentrated in the Advanced Antibiotics therapeutic category, with its top two products being Ceftriaxone and Cefixime, accounting for 100% of its export value. As of March 2026, the company employs approximately 96 professionals.

What Does Univentis Medicare Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ceftriaxone$5.5M 2Cefixime

Product Portfolio — Top 2 by Export Value

Univentis Medicare Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ceftriaxone	Advanced Antibiotics	$5.5M	111	1.9%	2
2	Cefixime	Advanced Antibiotics	$2.5M	50	1.4%	4

Univentis Medicare Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $8.1M. The top category is Advanced Antibiotics (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Univentis Medicare Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

The company's manufacturing operations are primarily based in Baddi, Himachal Pradesh, where its holding company, Innova Captab Limited, operates three manufacturing units. These facilities are licensed to manufacture products through two state-of-the-art manufacturing plants, adhering to WHO-GMP and EU-GMP standards.

3Key Leadership

The leadership team of Univentis Medicare Limited includes:

Manoj Kumar Lohariwala – Director
Vinay Kumar Lohariwala – Director
Anup Agarwal – Director
Riteshe Paltani – Whole-Time Director (appointed May 19, 2025)
Mahendar Korthiwada – Director (appointed April 28, 2022)

These individuals are responsible for the strategic direction and operational management of the company.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Univentis Medicare Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Univentis Medicare Limited's export activities are primarily focused on the Advanced Antibiotics category, with significant exports of Ceftriaxone and Cefixime. The company has engaged in 161 shipments totaling $8.1 million in export value. However, specific details regarding regulatory filings, approvals, and market access status in the US, EU, UK, Australia, and Japan are not publicly available. The company's concentration in a single therapeutic category and reliance on two products for its export revenue may pose risks related to market diversification and regulatory approvals.

2Emerging Markets

Univentis Medicare Limited's export data does not provide specific information on its presence in emerging markets such as Africa, Latin America, and Southeast Asia. The company's focus on Advanced Antibiotics suggests potential opportunities in these regions, especially if it holds WHO prequalification or other relevant certifications. However, without explicit data on regulatory approvals and market access, a comprehensive assessment of its position in these markets cannot be made.

3Geographic Strategy

Univentis Medicare Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Univentis Medicare Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export data does not indicate shipments to the United States, suggesting limited or no market presence in the U.S. Without FDA approvals, the company may face challenges in entering or expanding within the U.S. pharmaceutical market.

2WHO & EU GMP

Univentis Medicare Limited's holding company, Innova Captab Limited, operates manufacturing facilities that maintain WHO-GMP and EU-GMP certifications. These certifications are essential for ensuring product quality and compliance with international standards. However, specific details regarding WHO prequalification or EDQM status for Univentis Medicare Limited's products are not publicly available.

3CDSCO & Indian Regulatory

Univentis Medicare Limited is registered with the Ministry of Corporate Affairs under CIN U24232MH2015PLC402722. The company's manufacturing facilities are licensed to produce pharmaceutical products in compliance with Indian regulations. However, specific details regarding approvals from the Central Drugs Standard Control Organisation (CDSCO), state drug controllers, and export No Objection Certificates (NOCs) are not publicly available.

Univentis Medicare Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Univentis Medicare Limited operates in the competitive Advanced Antibiotics segment, with its top products being Ceftriaxone and Cefixime. While specific market share data is not available, the company's reliance on a limited product portfolio may impact its competitive positioning. Diversifying its product range and expanding into additional therapeutic areas could enhance its competitiveness in the global pharmaceutical market.

2Key Differentiators

Univentis Medicare Limited's key differentiators include its focus on high-quality, affordable medicines and its adherence to international manufacturing standards such as WHO-GMP and EU-GMP. These factors contribute to the company's reputation for quality and reliability in the pharmaceutical industry.

3Strategic Position

Univentis Medicare Limited's current strategic direction appears to be centered on the production and export of Advanced Antibiotics, particularly Ceftriaxone and Cefixime. The company's future outlook would benefit from diversifying its product portfolio, exploring new therapeutic areas, and expanding its presence in regulated markets to enhance growth and mitigate risks associated with market concentration.

Buyer Due Diligence Brief — Evaluating Univentis Medicare Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Univentis Medicare Limited's export data indicates a total export value of $8.1 million across 161 shipments, with a portfolio concentrated in the Advanced Antibiotics category. The company's adherence to WHO-GMP and EU-GMP standards reflects a commitment to quality manufacturing. However, the lack of diversification in its product portfolio and limited market presence in certain regions may impact its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and compliance:

WHO-GMP Certification: Confirms adherence to World Health Organization Good Manufacturing Practices. Verification can be done through the WHO official website or by contacting the manufacturer directly.

EU GMP Certification: Indicates compliance with European Union Good Manufacturing Practices. Verification can be conducted through the European Medicines Agency (EMA) or by reaching out to the manufacturer.

Frequently Asked Questions — Univentis Medicare Limited

How many pharmaceutical products does Univentis Medicare Limited export from India?

Univentis Medicare Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Ceftriaxone ($5.5M), Cefixime ($2.5M). Total export value is $8.1M.

What is Univentis Medicare Limited's total pharmaceutical export value?

Univentis Medicare Limited's total pharmaceutical export value is $8.1M, based on 161 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Univentis Medicare Limited cover?

Univentis Medicare Limited exports across 1 therapeutic categories. The largest are Advanced Antibiotics (100.0%, 2 products).

Get Full Univentis Medicare Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.